CHF response to the Report from the General Practice and Primary Care Clinical Committee: Phase 2

CHF supports the changes that the GPPCCC have been made in their Phase 2 Report and feel that their vision of the health system aligns closely with what we hear from members. We are pleased that our earlier comments have been taken on board but would like to see more detail around patient activation and the role of consumer leadership in the proposed changes to the MBS items. We believe that this element is essential to successful patient and family-centred primary health care in Australia. Beyond the scope of this Committee’s work, we would like to highlight the importance of strong change management to ensure recommendations align with consumer and sector expectations in the design, implementation and evaluation stages.

Read the CHF response to the Report from the General Practice and Primary Care Clinical Committee: Phase 2

CHF Response to the MBS Review Taskforce Diagnostic Medicine Clinical Committee  

CHF supports the DMCC’s recommendations in principle in order to reduce inappropriate requesting of pathology and Diagnostic Imaging tests. In particular, we feel that Clinical Decision Support is a platform to make quality a focus of requests and an opportunity for consumer education (informed clinical and financial consent). Beyond the scope of the DMCC’s work, we urge the government to implement Clinical Decision Supports quickly and consider the additional support and funding that will help the success of this process.

Read the CHF Response to the MBS Review Taskforce Diagnostic Medicine Clinical Committee  

Publication type: 
Publish date: 
Friday, March 8, 2019
Author: 
Consumers Health Forum